Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Maxim Group Downgrades Brooklyn to Hold

Maxim Group Downgrades Brooklyn to Hold

Maxim Group analyst Jason McCarthy downgrades Brooklyn (NASDAQ:BTX) from Buy to Hold.

byBenzinga Newsdesk

October 12, 2022

1 minute read

Maxim Group analyst Jason McCarthy downgrades Brooklyn (NASDAQ:BTX) from Buy to Hold.

NeuroBo Pharmaceuticals Submits IND Application To The FDA For A Phase 1 Clinical Trial Of DA-1726 For The Treatment Of Obesity

By Benzinga Newsdesk

December 28, 9:46 AM

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has submitted an Investigational New Drug (IND) application to

NRBO

Avadel Pharmaceuticals Files For Mixed-Securities Shelf Offering Of Up To $500M

By Michael Horton

August 31, 4:54 PM

-Reuters

AVDL

Analyst Ratings

Where PagerDuty Stands With Analysts

By Benzinga Insights

November 21, 5:00 PM

Within the last quarter, PagerDuty (NYSE:PD) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

Femasys Q2 EPS $(0.22) Up From $(0.52) YoY

By Benzinga Newsdesk

August 10, 4:45 PM

Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.22) per share. This is a 57.69 percent increase over losses of $(0.52) per share from the same period last year.

FEMY

Maxim Group Downgrades Brooklyn to Hold

Related Posts

NeuroBo Pharmaceuticals Submits IND Application To The FDA For A Phase 1 Clinical Trial Of DA-1726 For The Treatment Of Obesity

Avadel Pharmaceuticals Files For Mixed-Securities Shelf Offering Of Up To $500M

Where PagerDuty Stands With Analysts

Femasys Q2 EPS $(0.22) Up From $(0.52) YoY